HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, W.-S. Articles by Liu, R.-S. Search for Related Content PubMed PubMed Citation Articles by Huang, W.-S. Articles by Liu, R.-S.

Evaluation of Early-Stage Parkinson’s Disease with ^99mTc-TRODAT-1 Imaging

Departments of Nuclear Medicine, Neurological Surgery, and Neurology, National Defense Medical Center, Tri-Service General Hospital, Taipei; Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei; and Institute of Nuclear Energy Research, Lung-Tan, Taiwan, Republic of China

Parkinson’s disease is a progressive neurodegenerative disorder characterized by a selective loss of dopamine in the striatum. Problems remain in the accurate diagnosis of Parkinson’s disease. A ^99mTc-labeled tropane derivative that binds to dopamine transporter with high selectivity is [2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N2',S2,S2']oxo-[1R-(exo-exo)] (TRODAT-1). The purpose of this study was to investigate the potential usefulness of ^99mTc-TRODAT-1 imaging in the evaluation of patients with early-stage Parkinson’s disease. Methods: Thirty-four patients with early-stage idiopathic Parkinson’s disease were recruited. For all patients, the Parkinson’s disease was stage 2 or less as assessed by the Hoehn and Yahr scale. Seventeen age-matched healthy volunteers (8 men, 9 women) served as controls. ^99mTc-TRODAT-1 was prepared from a lyophilized kit. Brain SPECT imaging was performed between 165 and 195 min after injection, using a double-head camera equipped with fanbeam collimators. Specific uptake in the striatum and its subregions, including the putamen and caudate nucleus, was calculated and compared with that of the other sides and of healthy volunteers. Results: A continuous reduction in specific striatal uptake of ^99mTc-TRODAT-1 with increasing disease severity was found in Parkinson’s disease patients (control vs. stage I vs. stage II, 1.98 vs. 1.62 vs. 1.22, respectively, P < 0.01). The changes were magnified by measurement of specific putaminal uptake (control vs. stage I vs. stage II, 1.81 vs. 1.27 vs. 0.94, respectively, P < 0.01). The mean values of specific putaminal uptake contralateral to the more affected limbs were significantly decreased compared with the ipsilateral sides in both stage I and stage II groups (1.02 vs. 1.49 for stage I and 0.73 vs. 1.14 for stage II, P < 0.01). Moreover, a significant loss of putaminal uptake ipsilateral to the symptoms was found in the stage I group compared with the healthy volunteers (1.49 vs. 1.81, P < 0.01). The difference became greater when the posterior putaminal uptakes were compared. No remarkable adverse reactions were found in either healthy volunteers or Parkinson’s disease patients during or after imaging. Conclusion: For clinical practice, ^99mTc-TRODAT-1 may serve as a useful imaging agent for the early detection of Parkinson’s disease.

Key Words: ^99mTc-TRODAT-1 • dopamine transporter • SPECT • Parkinson’s disease

This article has been cited by other articles:

				R. J. Uitti, Y. Baba, N. R. Whaley, Z. K. Wszolek, and J. D. Putzke Parkinson disease: Handedness predicts asymmetry Neurology, June 14, 2005; 64(11): 1925 - 1930. [Abstract] [Full Text] [PDF]

				A. Siderowf, A. Newberg, K. L. Chou, M. Lloyd, A. Colcher, H. I. Hurtig, M. B. Stern, R. L. Doty, P. D. Mozley, N. Wintering, et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease Neurology, May 24, 2005; 64(10): 1716 - 1720. [Abstract] [Full Text] [PDF]

				Y.-H. Weng, T.-C. Yen, M.-C. Chen, P.-F. Kao, K.-Y. Tzen, R.-S. Chen, S.-P. Wey, G. Ting, and C.-S. Lu Sensitivity and Specificity of 99mTc-TRODAT-1 SPECT Imaging in Differentiating Patients with Idiopathic Parkinson's Disease from Healthy Subjects J. Nucl. Med., March 1, 2004; 45(3): 393 - 401. [Abstract] [Full Text]

				W. J. Hwang, W. J. Yao, S. P. Wey, and G. Ting Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease J. Nucl. Med., February 1, 2004; 45(2): 207 - 213. [Abstract] [Full Text] [PDF]

				C.-S. Lu, Y.-H. Weng, M.-C. Chen, R.-S. Chen, K.-Y. Tzen, S.-P. Wey, G. Ting, H.-C. Chang, and T.-C. Yen 99mTc-TRODAT-1 Imaging of Multiple System Atrophy J. Nucl. Med., January 1, 2004; 45(1): 49 - 55. [Abstract] [Full Text] [PDF]

				K. Marek, D. Jennings, and J. Seibyl Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa Neurology, September 23, 2003; 61(90063): S43 - 48. [Full Text]

				W.-S. Huang, Y.-H. Chiang, J.-C. Lin, Y.-H. Chou, C.-Y. Cheng, and R.-S. Liu Crossover Study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's Disease Patients J. Nucl. Med., July 1, 2003; 44(7): 999 - 1005. [Abstract] [Full Text] [PDF]